Edition:
United States

Medigene AG (MDG1k.DE)

MDG1k.DE on Xetra

18.00EUR
11:35am EST
Change (% chg)

€-0.45 (-2.44%)
Prev Close
€18.45
Open
€18.60
Day's High
€18.67
Day's Low
€17.84
Volume
205,251
Avg. Vol
280,618
52-wk High
€19.42
52-wk Low
€8.53

Chart for

About

Medigene AG is a Germany-based biotechnology company that develops treatment platforms to target various types and stages of cancer with candidates in clinical and pre-clinical development. The Company focuses on the development of personalized T cell-based immunotherapies. It develops three platforms: T-cell receptor (TCR)-modi... (more)

Overall

Beta: 1.24
Market Cap(Mil.): €411.45
Shares Outstanding(Mil.): 22.30
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 192.73 16.31
EPS (TTM): -- -- --
ROI: -- -0.67 35.74
ROE: -- -3.38 17.71

BRIEF-Medigene Receives Approvals For First Clinical Trial With MDG1011

* SAYS RECEIVES APPROVALS FOR ITS FIRST CLINICAL TRIAL WITH TCR THERAPY MDG1011

Feb 21 2018

BRIEF-Medigene Strengthens Its Patent Portfolio With US Patent On Tagged TCR

* MEDIGENE STRENGTHENS ITS PATENT PORTFOLIO WITH A US PATENT ON A TAGGED TCR Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Feb 01 2018

BRIEF-Medigene, RXi To Collaborate On Therapeutic T Cells

* MEDIGENE COLLABORATES WITH RXI PHARMACEUTICALS TO FURTHER SHARPEN ITS THERAPEUTIC T CELLS

Dec 11 2017

BRIEF-Medigene Sells US-Rights For Veregen, Raises 2017 Guidance

* PTA-ADHOC: MEDIGENE AG: MEDIGENE SELLS US-RIGHTS FOR VEREGEN® AND RAISES FINANCIAL GUIDANCE 2017

Dec 05 2017

BRIEF-Medigene to issue new shares to settle Trianta milestone payment

* Announces issuance and number of new shares to settle last Trianta milestone payment

Sep 07 2017

Earnings vs. Estimates